New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19 |
| September 30, 2021 | September 2021 Bond Updates |
|
TARRYTOWN, N.Y., Sept. 30, 2021 /PRNewswire/ -- Trial met primary endpoint, showing REGEN-COV significantly reduced viral load within 7 days of treatment; trial conducted in patients hospitalized with COVID-19 who did not require high-flow oxygen or mechanical ventilation at baseline... |
| View more at: https://www.prnewswire.com:443/news-releases/new-regen-cov-casirivimab-and-imdevimab-data-show-supportive-results-in-patients-hospitalized-with-covid-19-301388370.html |
| Related News |
|